Cervical cancer detection kit Gocsen®

geneticPAX1 genecell

Cervical cancer is a malignant tumor that seriously threatens women's health. Early diagnosis and treatment are crucial in reducing cervical cancer mortality rates. Cervical intraepithelial neoplasia (CIN, original CIN1) can be classified into low-grade squamous intraepithelial lesion (LSIL, original CIN2 and CIN3) and high-grade lesions (HSIL). Timely detection and treatment of HSIL, which has the potential to progress to invasive cervical cancer, are the main objectives in the management of cervical cancer, aiming to minimize the risk of invasive cervical cancer development. Research has revealed that genetic abnormal changes are a crucial mechanism in tumor development, and DNA methylation can induce tumor occurrence by silencing key tumor suppressor genes. PAX1 protein plays a significant role in embryonic development by regulating cell proliferation and inducing directed cell migration, contributing to the formation of essential organs. There is a close relationship between the highly methylated PAX1 gene promoter region and cervical cancer. Quantitative detection of PAX1 gene promoter methylation levels in cervical exfoliated cells can be utilized for cervical cancer screening and the management of precancerous lesions. The greatest advantage of PAX1 gene methylation testing lies in its high specificity, with its methylation level highly correlated with cytological grading and the severity of cervical lesions [2]. It can serve as a triage test after HPV testing is positive or when the TCT results show atypical squamous cells of undetermined significance (ASC-US) before colposcopy. By implementing PAX1 methylation testing, the number of unnecessary colposcopies